3 completed, 3 not yet recruiting, 3 recruiting. 3 Phase 2, 3 Phase 3, 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 4 | 2 | Not yet recruiting 2 |
| Phase 1 | 1 | Completed 1 |
Follow Neoplasms, Endometrial: new trials by email Literature Review of Neoplasms, Endometrial trials Research Report on Neoplasms, Endometrial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer Dostarlimab, Carboplatin and paclitaxel - Endometrial Carcinoma, Neoplasms, Endometrial | Phase 3 | Not yet recruiting | GlaxoSmithKline | 378 | 2026-11-12 | 2026-10-19 |
| A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02) Mocertatug rezetecan, Dostarlimab, Pembrolizumab - Neoplasms, Endometrial | Phase 3 | Recruiting | GlaxoSmithKline | 610 | 2026-09-24 | 2026-11-03 |
| A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer Dostarlimab, Carboplatin, Paclitaxel - Neoplasms, Endometrial | Phase 4 | Not yet recruiting | GlaxoSmithKline | 100 | 2026-08-17 | 2026-06-17 |
| A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) Mocertatug rezetecan, Paclitaxel, Doxorubicin - Neoplasms, Endometrial | Phase 3 | Recruiting | GlaxoSmithKline | 600 | 2026-06-04 | 2026-11-03 |
| A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) Dostarlimab, Carboplatin, Paclitaxel - Neoplasms, Endometrial | Phase 2 | Recruiting | GlaxoSmithKline | 30 | 2025-11-27 | 2025-12-22 |
| A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC) Dostarlimab - Neoplasms, Endometrial | Phase 4 | Not yet recruiting | GlaxoSmithKline | 100 | 2025-07-15 | 2025-07-08 |
| MK-3475 Immunotherapy in Endometrial Carcinoma MK-3475, Surgical resection (standard of care), Paclitaxel (standard of care) - Endometrial Cancer, Endometrial Carcinoma | Phase 1 | Completed | Washington University School of Medicine | 10 | 2016-02-05 | 2025-01-03 |
| A Trial for Patients With Advanced/Recurrent Endometrial Cancer pemetrexed - Neoplasms, Neoplasms by Site | Phase 2 | Completed | Eli Lilly and Company | 27 | 2006-09-01 | 2009-11-20 |
| Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer topotecan - Neoplasms, Endometrial, Endometrial Cancer | Phase 2 | Completed | GlaxoSmithKline | 70 | 2005-10-01 | 2012-07-11 |
Endometrial Neoplasms (9) · Genital Neoplasms, Female (1) · Neoplasms (1) · Neoplasms by Site (1) · Urogenital Neoplasms (1) · Uterine Neoplasms (1)
Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genital Diseases (9) · Genital Diseases, Female (9) · Urogenital Diseases (9) · Uterine Diseases (9) · Genital Neoplasms, Female (8) · Neoplasms (8) · Neoplasms by Site (8) · Urogenital Neoplasms (8) · Uterine Neoplasms (8) · Male Urogenital Diseases (1)
Paclitaxel (5) · dostarlimab (5) · Carboplatin (4) · pembrolizumab (2) · Doxorubicin (1) · Pemetrexed (1) · Radiation (1) · Standard of Care (1) · Topotecan (1)
GlaxoSmithKline (7) · Eli Lilly and Company (1) · Washington University School of Medicine (1)
United States (4) · Canada (3) · Japan (2) · South Korea (2) · Argentina (1) · Australia (1) · Brazil (1) · China (1) · Hungary (1) · Israel (1) · Panama (1) · United Kingdom (1)
David Miller, MD (1) · Premal Thaker, M.D., MSc. (1)
2025 (3)